Embla Medical hf./DKr EMBLA
07:00
09:00
11:00
12:55
14:55
1D1W1MYTD1Y5YMAX
About Embla Medical hf.
Embla Medical hf., headquartered in Reykjavik, Iceland, specializes in non-invasive orthopedic products, focusing on prosthetics, neuro orthotics, bracing, and supports. The company operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. Its product portfolio includes mechanical and bionic prosthetic devices, bracing solutions for various body parts, and patient care services for individuals with limb loss or musculoskeletal conditions. Originally founded as Össur hf. in 1971, the company rebranded to Embla Medical hf. in April 2024 to reflect its expanded scope and unified purpose. Embla Medical serves a global market, with operations across Europe, the Middle East, Africa, the Americas, and the Asia-Pacific regions. The company's strategic positioning is strengthened by its diverse brand portfolio, including Össur, Fior & Gentz, College Park, and ForMotion, enabling it to offer comprehensive mobility solutions worldwide.
Ticker
DKr EMBLA
Sector
Primary listing
CSE
Employees
4,500
Headquarters
Reykjavik, Iceland
Website
EMBLA Metrics
BasicAdvanced
kr 11bn
20.80
kr 1.30
0.45
-
Price and volume
Market cap
kr 11bn
Beta
0.45
52-week high
kr 37.90
52-week low
kr 25.00
Average daily volume
209k
Financial strength
Current ratio
1.208
Quick ratio
0.628
Long term debt to equity
40.207
Total debt to equity
61.128
Interest coverage (TTM)
6.56%
Profitability
EBITDA (TTM)
967.604
Gross margin (TTM)
61.97%
Net profit margin (TTM)
8.94%
Operating margin (TTM)
13.09%
Effective tax rate (TTM)
22.58%
Revenue per employee (TTM)
kr 1,352,270
Management effectiveness
Return on assets (TTM)
4.76%
Return on equity (TTM)
10.10%
Valuation
Price to earnings (TTM)
20.797
Price to revenue (TTM)
1.858
Price to book
12.8
Price to tangible book (TTM)
-347.96
Price to free cash flow (TTM)
18.45
Free cash flow yield (TTM)
5.42%
Free cash flow per share (TTM)
1.463
Growth
Revenue change (TTM)
11.71%
Earnings per share change (TTM)
19.15%
3-year revenue growth (CAGR)
9.50%
10-year revenue growth (CAGR)
7.08%
3-year earnings per share growth (CAGR)
24.84%
10-year earnings per share growth (CAGR)
5.77%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs